Sign in
Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib
Journal article   Open access  Peer reviewed

Extended progression-free survival in two patients with alveolar soft part sarcoma exposed to tivantinib

John M Goldberg, Tara Gavcovich, Gaurav Saigal, Jonathan W Goldman and Lee S Rosen
Journal of clinical oncology, Vol.32(34), pp.e114-e116
2014-12-01
PMCID: PMC4876351
PMID: 24550414

Abstract

Proto-Oncogene Proteins c-met - metabolism Sarcoma, Alveolar Soft Part - enzymology Proto-Oncogene Proteins c-met - antagonists & inhibitors Humans Thigh Male Tomography, X-Ray Computed Treatment Outcome Antineoplastic Agents - administration & dosage Quinolines - administration & dosage Sarcoma, Alveolar Soft Part - drug therapy Sarcoma, Alveolar Soft Part - secondary Pyrrolidinones - administration & dosage Disease-Free Survival Protein Kinase Inhibitors - administration & dosage Time Factors Adolescent Female Chemotherapy, Adjuvant Child Sarcoma, Alveolar Soft Part - diagnosis
url
https://doi.org/10.1200/JCO.2013.48.7462View
Published (Version of record) Open

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.118 Soft Tissue, Bone & Nerve Cancers
1.118.300 Rhabdomyosarcoma
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details